radiotherapyImmunotherapysurgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
radiotherapy: Definitive radiotherapy or radiotherapy-based combined modality therapy
Immunotherapy: Immune checkpoint inhibitors as monotherapy or in combination with other therapies
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines: Radical esophagectomy with or without neoadjuvant/adjuvant therapy
Study summary
This single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. Adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between January 2017 and December 2024 were consecutively enrolled. Patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
1. Waiver of informed consent for deceased or lost-to-follow-up patients (January 2017-March 2024)
2. Voluntary signed informed consent from surviving patients who could be contacted
3. Treatment at Nanfang Hospital, Southern Medical University (January 2017-December 2024)
4. Received antitumor therapy for esophageal cancer
5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
Exclusion Criteria:
1. Concurrent other malignancies
2. Patients deemed ineligible by investigators
Primary outcome measure(s)
Overall Survival (OS) — From the date of treatment initiation to the date of death from any cause,assessed up to 120 months. The length of time from the start of treatment until death from any cause, evaluating the long-term survival benefit of the combined therapy.
Trial sites (1)
Facility
City
Region
Status
Nanfang Hospital, Southern Medical University
Guangzhou
Guangzhou
More Nanfang Hospital, Southern Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.